CD274 and hepatocellular carcinoma: proved that combination therapy with Atezolizumab (anti-PD-L1) plus Bevacizumab (anti-VEGF monoclonal antibody) increases OS and PFS of HCC patients and replaced as the primary chemotherapy line in advanced HCC patients (180).